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Abstract: Inflammatory bowel diseases (IBDs) develop in genetically predisposed individuals in
response to environmental factors. IBDs are concomitant conditions of industrialized societies, and diet
is a potential culprit. Consumption of ultra-processed food has increased over the last decade in
industrialized countries, and epidemiological studies have found associations between ultra-processed
food consumption and chronic diseases. Further studies are now required to identify the potential
culprit in ultra-processed food, such as a poor nutritional composition or the presence of food additives.
In our review, we will focus on food additives, i.e., substances from packaging in contact with food,
and compounds formed during production, processing, and storage. A literature search using PubMed
from inception to January 2019 was performed to identify relevant studies on diet and/or food additive
and their role in IBDs. Manuscripts published in English from basic science, epidemiological studies,
or clinical trials were selected and reviewed. We found numerous experimental studies highlighting
the key role of food additives in IBD exacerbation but epidemiological studies on food additives on
IBD risk are still limited. As diet is a modifiable environmental risk factor, this may offer a scientific
rationale for providing dietary advice for IBD patients.
Keywords: colitis; food additive; diet; emulsifiers; high salt diet; inflammatory bowel diseases
1. Introduction
The most common types of inflammatory bowel diseases (IBDs) are Crohn’s disease (CD)
and ulcerative colitis (UC). IBD etiology is unknown, but IBDs develop in genetically predisposed
individuals in response to environmental factors and the result of an exacerbated mucosal immune
response to intestinal microbiota. IBDs are concomitant conditions of industrialized societies [1].
Indeed, IBD prevalence has continued to increase in Western countries, and newly industrialized
countries in Asia, the Middle East, Africa, and South America have exhibited a rapid increase of IBD
prevalence [1].
Environmental factors are supposed to play a decisive role in the pathogenesis of IBDs. Diet is
considered to be a potential culprit and we previously reviewed the potential effect of specific nutrients
in IBDs [2]. With this study, we aimed to focus on another potential dietary culprit: food additives.
Consumption of ultra-processed food (UPF) has increased over the last decade, in particular in
industrialized societies [3–5], and studies from the French web-based NutriNet-Santé cohort have
found an association between UPF consumption and chronic diseases, such as a higher cancer risk [6].
Nutrients 2019, 11, 1111; doi:10.3390/nu11051111 www.mdpi.com/journal/nutrients
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UPF now represent an important part of the diet of French individuals: UPF accounted for 16% of
food consumed by weight, corresponding to 33% of total energy intake [7]. In addition, the authors
also reported an association between these dietary patterns and a higher irritable bowel syndrome
risk (OR Q4 vs. Q1 [95% CI]: 1.25 [1.12–1.39], p-trend < 0.0001) [7]. Similar associations between UPF
consumption and chronic diseases are globally observed, such as metabolic syndrome in the US [4]
or depression in Spain [5]. Further studies are now required to identify the potential culprit in UPF,
such as a poor nutritional composition or the presence of food additives. In our review, we will focus
on food additives, i.e., substances from packaging in contact with food, and compounds formed during
production, processing, and storage.
2. IBD Patients and Dietary Beliefs
Diet is a crucial point for IBD patients [8–10] and exclusion diets are commonly reported.
In a French study, the dietary beliefs of 244 IBD patients were studied using a questionnaire of
14 items [8]. The majority of IBD patients (58%) believed that food can play a role in causing a relapse
and this strongly affects quality of life because IBD patients may refuse outdoor dining for fear of causing
IBD symptoms [8]. In a study conducted in the UK, 400 IBD patients received a dietary questionnaire
and data from this study were in accordance with the French study. In this study, deteriorating
symptoms were associated with certain foods from 60% of IBD patients [10]. Similar results were found
in a Dutch study conducted in 294 IBD patients through an online questionnaire [9]. Interestingly,
81% of IBD patients from the Dutch study reported that their main nutritional knowledge came from
their own experience, while 71% reported that they received professional dietary advice mainly from
dieticians [9]. In a Spanish study, the majority of IBD patients (86%) refrained from eating some foods
to avoid a worsening of flare-ups [11]. In pediatric IBD populations, food avoidance is also commonly
reported for 53% of patients [12].
3. A Pinch of Salt
Processed food is a high provider of dietary sodium chloride (NaCl). Few recent studies have
evaluated the potential impact of dietary salt in colitis models [13–15] (Figure 1). Tubbs et al. calculated
the NaCl content of a series of available foods in grocery and fast food restaurants using the SELF
Nutrition database, and they reported that these foods contained approximately 4% w/w NaCl [13].
Increased concentration of NaCl from 10 to 80 mM induced inflammatory cytokine production, such
as the IL (interleukin)-23/IL-17 pathway in normal intestinal lamina propria mononuclear cells [14].
High-salt diet (HSD) exacerbated chemically induced colitis, while pharmacological inhibition of
p38/MAPK abrogated its effect in both models [14]. Tubbs et al. demonstrated the deleterious effect
of HSD in numerous colitis models, such IL-10-/- or infectious colitis [13]. Interestingly, Aguiar et al.
reported that dietary salt exacerbated colitis but by itself can trigger gut inflammation by increasing
intestinal permeability and inflammatory histological score [15]. More recently, HSD also has been
shown to have a deleterious impact on intestinal microbiota by decreasing Lactobaccilus levels and
short-chain fatty acid production [16].
These studies raised the potential role of dietary salt as an environmental trigger for IBD
development by creating a deleterious environment that is more vulnerable to inflammatory insults.
Dietary phosphate has been less studied than dietary salt. Nevertheless, dietary inorganic
phosphate is abundant in processed food as a food additive, in particular in fast foods and processed
meats. Phosphate intake is two or three times higher [17]: 1655 mg/day for men and 1190 mg/day for women
in the US compared to dietary reference intake at 700 mg/day in industrialized countries. Its deleterious
effect on intestinal inflammation has also been demonstrated. Sugihara et al. fed Sprague–Dawley rats
with a diet containing 0.5% to 1.5% phosphate for 7 days before colitis induction [18]. As standard
animal diet contains approximatively 5000 mg/kg of phosphate, i.e., 0.5%, the range of phosphate from
0.5% to 1.5% used in the study mimics the human exposure range from 1- to 3-fold of the recommended
dietary intake. Dietary phosphate exacerbates colitis by accentuating body weight loss by increasing
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disease activity index and by activating NF (Nuclear factor)-κB [18]. The authors of the study also
found an in vitro increased inflammatory response by 2 mM phosphate in liposaccharide (LPS)-treated
RAW264 cells [18].
To our knowledge, only one study has reported clinical data concerning salt consumption and
IBDs [19]. In a US cohort from 194,711 women, the authors of this study reported that dietary intake of
potassium (Ptrend = 0.005) but not sodium (Ptrend = 0.440) was inversely associated with risk of CD [19].
The authors did not observe any significant association between both dietary potassium and sodium
and UC risk [19].
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Figure 1. High-salt diet promotes intestinal inflammation. High-salt diet exposure led to higher
intestinal permeability and dysbiosis. High-salt diet induced p38 MAPK phosphorylation and NFAT5
in lamina propria mononuclear cells activation with a subsequent expression of inflammatory cytokines
expression such as IL17, IL22, and TNFα.
4. Take the Bitter with the Sweet
Carbohydrates are obviously part of a normal diet but their excessive consumption is a feature
of the Westernized diet. In addition, industrialized food contains hidden sugars, such as lactose as
a texturing agent in sausages. There is currently no evidence of an association between carbohydrate
intake and IBD risk in epidemiological studies [20]. Results from the prospective EPIC (European
Prospective Investigation into Cancer and Nutrition) study, when excluding cases occurring within
the first 2 years after dietary assessment, found a positive association between a “high sugar and soft
drinks” pattern and UC risk (1.68 [1.00–2.82]; Ptrend < 0.05). When the authors considered the foods
most associated with the pattern, high consumers of sugar and soft drinks were at higher UC risk only
if they had low intakes of vegetables [21], but the amount of consumed sugar was not mentioned.
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Those with pediatric IBDs had a lower intake of carbohydrates compared to the general population,
in particular a decreased intake of food types high in sugar [12].
Polysaccharides are commonly added in UPF as emulsifiers, coating agents, stabilizers, or bulking
agents. These ingredients enable a better palatability and a longer shelf like of these products. Some of
these ingredients have been studied in experimental models of IBDs [22–25].
Nickerson et al. focused their studies on the effect of the dietary polysaccharide maltodextrin to
bacterial-induced intestinal inflammation [22–24]. Maltodextrin is commonly found in processed food
and medications. Nickerson et al. demonstrated that maltodextrin can promote Salmonella survival in
multiple cell types [24]. They also studied the effect of maltodextrin on CD-associated adherent-invasive
Escherichia coli (AIEC) and found that the presence of maltodextrin enhanced AIEC adhesion by a better
biofilm formation [22]. Maltodextrin consumption may promote intestinal dysbiosis and contribute
to disease susceptibility. In a recent study, maltodextrin in drinking water exacerbated intestinal
inflammation in an indomethacin-induced enteropathy model or in DSS (Dextran sodium sulfate)-colitis.
The mechanisms behind maltodextrin’s deleterious effects involved endoplasmic reticulum stress and
led to mucin-2 depletion [25].
The consumption of sweeteners is becoming more and more frequent in the US general population.
A recent study on 16,942 participants reported that 25% of children and 41% of adults in the US consumed
foods and beverages containing low-calorie sweeteners [26]. Two large Swedish prospective cohort
studies consisting of 83,042 participants did not find any association between sweetened beverages
consumption and risk of later-onset CD or UC [27]. In South Korea, food additive consumption (such as
sucralose) cannot explain the increased incidence of IBDs [28]. Increased IBD incidence started before
the 1980s in South Korea, while sucralose was only approved in 2000 [28]. A recent study demonstrated
the deleterious impact of an artificial sweetener called Splenda in experimental IBDs [29]. Splenda
contains 1% sucralose and 99% maltodextrin. The authors of this study investigated the impact of
6 weeks of supplementation with Splenda in SAMP1/YitFc mice that spontaneously developed ileitis.
Splenda supplementation induced ileal myeloperoxidase activity and promoted dysbiosis, in particular
an expansion of proteobacteria [29].
Carrageenan is a polysaccharide commonly used as a food additive. In experimental models,
it is also commonly used to induce an inflammatory response in vitro or in vivo [30,31]. The daily
consumption of carrageenan in the US diet is approximatively 250 mg per adult. Recently, a small
clinical trial was conducted to evaluate the potential benefit of a carrageenan-free diet in UC patients [32].
Patients were instructed to follow a carrageenan-free diet by avoiding carrageenan-containing-food and
received either 100 to 200 mg of carrageenan capsules or placebo capsules. Carrageenan-supplemented
patients had some higher inflammatory parameters, such as a higher clinical disease index and higher
IL-6 and fecal calprotectin [32]. Carrageenan also has an impact on intestinal microbiota [33]. Colitis
induction by carrageenan at 20 mg/L in drinking water decreased the level of an anti-inflammatory
bacteria Akkermansia muciniphila [30].
Chassaing et al. did a remarkable study on two emulsifiers, carboxymethylcellulose (CMC) and
polysorbate-80 (P80), on gut barrier [34–36]. They added emulsifiers in the mouse drinking water
at a relative low level for 12 weeks in wild-type or IL-10-deficient mice [35]. Dietary emulsifiers
altered gut microbiota composition and induced hyperpermeability [35]. Emulsifiers promote colitis
in IL-10-/- mice by increasing inflammatory markers such as fecal lipocalin-2 or myeloperoxidase
activity [35]. They demonstrated microbiota involvement in mediating the emulsifier effect by
transferring intestinal microbiota from emulsifier-treated mice into unexposed germ-free mice; upon
doing so, they observed that colonized germ-free mice had the same response [35]. They confirmed
in a second study the direct impact of the emulsifiers on the microbiota using a mucosal simulator
of the human intestinal microbial ecosystem; they observed that emulsifiers-promoted flagellin
levels [36]. In another study, Chassaing et al. investigated whether emulsifiers can impact colon
carcinogenesis [34]. They exposed mice with colitis-associated cancer to the same emulsifiers for
13 weeks and they observed that emulsifiers promote carcinogenesis through intestinal microbiota
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alteration, the establishment of a pro-inflammatory environment, and increased proliferation marker
Ki67 [34]. Interestingly, they demonstrated in a recent study that emulsifiers also had a significant
impact on anxiety [37], and psychological co-morbidities are commonly observed in IBD patients and
IBD experimental models [38].
One-third of IBD patient underwent irritable bowel syndrome-like symptoms [39] and a recent
meta-analysis confirmed that dietary restriction of fermentable oligosaccharide, disaccharide,
monosaccharide, and polyol (FODMAP) reduced functional gastrointestinal symptoms such as
bloating [40]. In heathy volunteers, mechanisms behind low-FODMAP diet involved decreased
Bifidobacterium and reduced breath hydrogen [41].
5. Put the Pedal to the Metal
Aluminum is an abundant element commonly used in our environment. It is used in processed
foods and cooking materials such as food packaging or foils. Cosmetic products and drugs are also
a source of aluminum. The European Food Safety Authority set the tolerable weekly intake of 1 mg
aluminum/kg body weight. Pineton de Chambrun et al. investigated the dietary effect of aluminum
in colitis models. The strength of this study from Lille University is that the aluminum dose of
1.5 mg/kg/day that they used was relevant to human exposure [42]. Four weeks of oral administration
of aluminum has been shown to worsen chemically-induced colitis models. Indeed, macroscopic
and histologic scores and myeloperoxidase activity were higher in colitis mice exposed to aluminum.
They also found a similar effect in IL-10-/- mice. Exposure of epithelial cells lines with aluminum
phosphate increased constitutive or LPS-induced cytokines mRNA level. Interestingly, aluminum
exposure also delays mucosal repair capacity by inhibiting proliferating processes [43]. IBD patients
often suffer from visceral pain even in remission periods [39], and a recent study from the same team
has shown that dietary exposure of aluminum also induced visceral hypersensitivity in rodents [44].
This effect persisted over time after treatment cessation and involved mast cell activation [44].
6. To Add or Not to Add
Titanium dioxide (TiO2) is a food pigment which increases opacity and confers a white color [45].
Dietary sources of TiO2 are numerous, from sweets to toothpaste, and it is often used to provide
a natural whiteness and opacity to foods, such as icing on cakes. TiO2 has an optimal particle diameter
of 200–300 nm, but a nano-sized fraction can be found because of manufacturing processes. These TiO2
nanoparticles, in Europe listed as E171, are commonly used as a food additive. We previously
investigated the effects of microparticles on macrophages from CD patients, and we observed that
microparticles alone did not induce an immune response [46]. By contrast, microparticles act as
adjuvants to induce potent cytokine responses in the presence of bacterial antigens such as LPS [46].
In addition, macrophage function has been shown to be impaired in the presence of high concentrations
of microparticles [46]. Houdeau et al. investigated the specific effect of E171 on gut barrier [47]
at a relevant range for human exposure, because modeling of human exposure to TiO2 estimates
an exposure of 2–3 mg/kg/day for children under the age of ten [48]. After one week of dietary exposure
to TiO2 at 10 mg/kg, titanium can be detected in Peyer’s patches in rats [47] and it is associated
with an unfavorable immune cell balance: an increased CD11b/c+ CD103+ MHC-II+ dendritic cell
proportion and a decreased proportion of regulatory T cells [47]. This TiO2 effect is not transient
because it lasts after 100 days of TiO2 treatment [47]. In addition, long-term exposition for 100 days is
associated with low-grade colon inflammation and induced aberrant crypt foci in a chemically induced
carcinogenesis model [47]. The effect of dietary exposure to titanium dioxide at 50 to 500 mg/kg
on colitis development has been investigated [49]. Dietary titanium dioxide exacerbates acute DSS
colitis by inducing a shortening of the colon and increasing infiltration and histological inflammatory
scores [49]. The same experiment was performed in inflammasome Nlrp3-/- mice, and the results
showed that dietary TiO2 at 500 mg.kg−1 did not reproduce colitis exacerbation in Nlrp3/- compared
to the response of the wild type mice. The mechanisms behind the dietary effect of TiO2 on colitis
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involved NLRP3. In vitro works demonstrated the accumulation of TiO2 in human intestinal epithelial
and macrophage cell lines in a dose-dependent manner [49]. In addition, TiO2 at 20 to 100 µg/mL
stimulates oxidative stress and increased intestinal permeability in human intestinal epithelial cell
lines. Rogler et al. found that patients with active UC exhibited increased blood levels of titanium [49].
In extra-intestinal organs, dietary exposure at 2.5 to 10 mg/kg to TiO2 for 6 months upregulated
renal TGFβ and SMAD, signaling pathways involved in fibrosis [50]. We speculate that dietary
TiO2 may also promote IBD-induced intestinal fibrosis, but this effect has not been yet documented.
Two recent studies have proposed a dietary intervention to counteract TiO2-induced inflammation in
mice. The administration of both flavonoids naringenin or quercetin inhibits TiO2-induced arthritis by
decreasing cytokine production and oxidative stress [51,52].
Oral bisphenol A is a chemical used in food packages. Oral bisphenol A at a dose lower to the
tolerable daily intake was able to induce intestinal hyperpermeability in rats, and this effect occurs
in a dose-dependent manner [53]. In trinitrobenzene sulfonic acid (TNBS)-induced colitis, perinatal
exposure of dietary bisphenol A increased myeloperoxidase activity in female rats but not in male
rats [53].
Dietary bisphenol A induced visceral hypersensitivity in response to colorectal distension [53].
A recent study highlighted the effect of bisphenol A in chemically induced colitis in ovariectomized
female mice, and the authors demonstrated that bisphenol A exposure led to a worsened colitis through
intestinal microbiota metabolites, such as a decreased level of tryptophan [54].
Food heat treatment leads to neoformed compounds such as Maillard reaction products. Exposure
to these Maillard reaction products alleviated inflammatory response [55] and dysbiosis in colitis
models [56].
7. Exclusion Diets
Exclusion diets are commonly followed by IBD patients [57]. These exclusion diets have poor or
no scientific rationale but expose IBD patients to nutritional deficiencies. The last European Society for
Clinical Nutrition and Metabolism (ESPEN) guidelines about clinical nutrition in IBD patients declared
that there is no IBD diet in active disease (strong consensus—96% agreement) [58]. We will limit our
section to a few exclusion diets that may explain some benefits to limit food additive exposure.
Exclusive enteral nutrition (EEN) is recommended as first intention treatment to induce remission
in children or teenagers with CD [58], although EEN is not recommended in adult patients.
The mechanisms behind EEN are not fully understood, but it may involve dysbiosis correction
or gut barrier maintenance [59]. EEN mechanisms may also involve the absence of specific deleterious
food components, such as food additive exposure.
There is also concern about the presence of pesticides in the food chain, although there is still no
evidence connecting pesticides to IBDs [60]. A recent study from the NutriNet French cohort found
that more frequent organic food consumption decreased cancer risk [61].
We previously mentioned the effect of nanoparticles in gut barrier dysfunction in preclinical
models, and two clinical trials have investigated the impact of low or microparticle-free diet in IBD
patients. The first one was a very small trial in 20 CD patients that showed a beneficial effect of low or
microparticle-free diet in ileal CD patients, such as decreased corticosteroids intake [62].
The second study included 84 active CD patients for 16 weeks [63] and the authors did not find
any benefit of the microparticle exclusion on inflammatory disease activity index, fecal calprotectin,
or intestinal permeability [63]. We previously reported the effects of carrageenan on gut barrier in
preclinical models. A small pilot study investigated the effect of carrageenan-free diet in 12 UC
patients [32]. Three out of ten UC patients who followed the carrageenan-free diet for 12 months
relapsed compared to three out of five patients in the control group (RR (Relative risk) 0.50, 95% CI
0.15 to 1.64), but it may be difficult to conclude that there are potentially beneficial effects because of
the very small size of the study.
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Lactose-free diets are common in IBD patients. In a small recent study on 78 IBD patients from
Iceland, 60% (47 patients) reported limiting their dairy consumption or even excluding it, but only
eight of them used calcium supplements [64]. Acquired lactase deficiency is commonly reported in CD
patients, in particular in proximal CD. In a clinical trial in 77 UC patients published in 1965, milk-free
diets had only a benefit for one out of five patients [65] and did not justify dairy-restricted diets in all
IBD patients. In 29 pediatric UC patients, exclusion of cow milk proteins had no influence on induction
and/or maintenance of remission [66].
Paleolithic diet is another exclusion diet without scientific rationale. Its principles are that our
gastrointestinal system did not evolve alongside our modernized diet and may explain numerous
inflammatory diseases. This diet excludes a lot of foodstuffs, such as ultra-processed foods or cereals,
and is limited to wild meats and a non-cereal, plant-based diet. To our knowledge, the only published
data about paleo diet and IBDs is a Hungarian case report about a teen CD patient’s refractory to
treatments. This CD patient had a clinical remission after 2 weeks on a paleo diet and was still in
remission 15 months later [67]. Extrapolation from a unique case control study is not permitted,
and exclusion of so many foodstuffs may be associated with numerous nutritional deficiencies.
One-third of IBD patients underwent IBS-like symptoms, and partial exclusion of some fermentable
components may be associated with benefits to functional symptoms. For example, in a small study
with 16 CD patients in remission, a strict exclusion diet of wheat and dairy products for 2 weeks
significantly decreased function symptoms such as abdominal pain [68]. In a prospective study with
89 IBD patients in remission, a low-FODMAP diet for 6 weeks reduced IBS-like symptoms while it
increased quality of life in patients [69].
Exclusion diets are not recommended and may expose patients to numerous nutritional deficiencies.
In addition, cofounding factors are often observed, leading to unjustified dietary exclusion. Recently,
a double-blind clinical trial identified that fructan composition, instead of gluten, induced functional
symptoms in patients with self-reported non-celiac gluten sensitivity [69]. Similar results were
previously reported concerning lactose intolerance [70]. Avoiding some foods has been identified as
a risk factor for malnutrition in IBD patients in a Spanish cohort [71]. Of note, malnutrition increased
further complications, such as higher surgery and hospitalization rates, and malnutrition is associated
with altered quality of life in IBD patients [11,72]. In addition, exclusion diets may limit socializing and
dining because many IBD patients reportedly refused dining out because doing so would not conform
with their exclusion diet [11]. Exclusion of dairy products such as in a lactose-free diet or paleo diet
may increase osteoporosis risk in IBD patients, while gluten-free diets are associated with decreased
microbiota diversity.
8. Conclusions
Diet is a modifiable environmental risk factor and food additives may act as potentiators of
disease. Diet is a crucial point for IBD patients and exclusion diets appear to offer an alternative
allowing for relative control of disease development. Nevertheless, the last ESPEN guidelines did
not recommend any exclusion diet for induction or maintenance of remission in IBD patients but
advised IBD patients to undergo counselling by a dietitian to avoid malnutrition. In addition, it has
been recently reported that IBD patients in remission have an unbalanced dietary profile for essential
nutrients [73]. Rather than exclusion diets, home-made food may be prioritized to decrease food
additive amounts and enable patients to control their exposure to many hidden ingredients, such as
added salt or sugars. Home-made food is already recommended in the last nutritional guidelines in
France and, contrary to exclusion diets, cooking can represent a form of a convivial time, allowing
a better quality of life with increased socialization. In addition, obesity is more and more frequent
in IBD patients [74] and food preparation from scratch may be associated with a decreased risk of
obesity [75] or decreased amount of dietary energy from ultra-processed food [76].
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Abbreviations
AIEC Adherent-invasive Escherichia coli
CD Crohn’s disease
CMC carboxymethylcellulose
EEN exclusive enteral nutrition
ESPEN European Society for Clinical Nutrition and Metabolism
FODMAP fermentable oligosaccharide, disaccharide monosaccharide, and polyol
HSD High-salt diet
IBD inflammatory bowel diseases
LPS liposaccharide
NFAT5 nuclear factor of activated T cells 5
NLRP NOD-like receptor pyrin
P80 polysorbate-80
SCFA short-chain fatty acid
SMAD small mothers against decapentaplegic
TNBS trinitrobenzene sulfonic acid
TiO2 titanium dioxide
UC ulcerative colitis
UPF ultra-processed food
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